© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Tibsovo

A Promising New Treatment for Some People with Acute Myeloid Leukemia

Ivosidenib (Tibsovo) plus chemotherapy may soon be an option for those with leukemia that has an IDH1 mutation.
Pancreas and gall bladder

FDA Approves Tibsovo Targeted Therapy for Cholangiocarcinoma

The IDH1 inhibitor is the third medication approved this year for hard-to-treat bile duct cancer.
Pancreas and gall bladder

Tibsovo Could Be First Targeted Therapy for Cholangiocarcinoma

IDH1 inhibitor delayed progression of this often aggressive cancer of the bile ducts.

Tibsovo

FDA Approves First Targeted Treatment for Leukemia Patients With IDH1 Genetic Mutation

Tibsovo led to complete remission in some people with acute myeloid leukemia.
Advertisement

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.